EVALUATION OF OCULAR FILMS OF OFLOXACIN FOR ANTIBACTERIAL ACTIVITY
Objective: The current study emphasizes on the treatment of ocular infection with objectives of reducing the frequency of administration, obtaining controlled release and greater therapeutic efficacy of the drug (ofloxacin) using ocular films.
Methods: Ocular films were designed by solvent evaporation method containing a different combination of polymers. The folding endurance (mechanical strength) was determined by the number of folds at a specific single place required to break the film into two parts. Thickness was measured using screw gauze. The surface pH was done by pH paper. The percentage moisture absorption was carried out by placing the ocular films in a desiccator containing ammonium chloride. Percentage moisture loss was carried out by placing the ocular films in the desiccator containing anhydrous calcium chloride. in vitro drug release study were carried by using a modified version of franz diffusion cell. Stability study were carried using stability chambers as per ICH guidelines. The antibacterial activity was performed by using male albino rabbits.
Results: The thickness and folding endurance of the films were in the range of 44Â±1.1 to 92Â±1.8 and 4.5Â±0.6 to 6.8Â±0.3, respectively for different formulations. Surface pH was evaluated in the range of 6.6 to 7.2. Percentage moisture absorption and percentage moisture loss were evaluated in the range of 1.17Â±1.1 to 6.72Â±1.5 and 0.58Â±0.9 to 1.23Â±0.9 respectively. Microbial growth was not observed in any formulation during sterility testing. The drug release for different batch codes PAH, PBE, PCP, PDC, PEEH, and PFEC was found to be 96.2, 56.9, 93.4, 94.5, 98.4 and 95.9 % respectively up to 12 h. Ocular films of batch code PEEH was optimized for maximum drug release (98.4%). The antibacterial effect was noted periodically (01 to 05 d) after administration of sterile formulation in the treated eyes vs. control eyes of each rabbit. The optimized batch PEEH of ocular films reduced the infection and redness completely within 3 d in a single dose.
Conclusion: The optimized formulation would be able to offer benefits such as increased residence time, prolonged drug release, reduced frequency of administration and improved patient compliance with complete removal of inflammation and redness from the cul-de-sac.
2. Sreenivas SA, Hiremath SP, Godbole AM. Ofloxacin ocular inserts: design, formulation and evaluation. Iranian J Pharmacol Ther 2006;5:159-62.
3. Peneva PT. Non-steroidal anti-inflammatory drugs for topical ophthalmic administration: contemporary trends. Int J Pharm Pharm Sci 2015;7:13-9.
4. Gaudana R, Jwala J, Boddu SHS, Mitra AK. Recent perspectives in ocular drug delivery. Pharma Res 2009;26:1197-216.
5. Smith SE. Ocular NSAIDs. Therapeutics; 2005. p. 124-7.
6. Chien YW. Novel drug delivery systems (Drugs and the pharmaceutical sciences). New York: Marcel Dekker Inc., Second Edition; 1996.
7. Kothawade SN, Deshpande ST, Lunkad AS, Dighe PA. Formulation and in vitro characterization of ketorolac tromethamine ophthalmic inserts. Res J Pharm Dosage Forms Tech 2014;5:311-4.
8. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opinion Pharmacother 2006;7:99â€“107.
9. Patel DH, Patel MP, Patel MM. Formulation and evaluation of drug-free ophthalmic films prepared by using various synthetic polymers. Pharmaceutics 2009;1:116-20.
10. Sankar V, Chandrasekaran AK, Durga S, Geetha G, Ravichandra V, Vijayakumar A, et al. Design and evaluation of diclofenac sodium ophthalmic inserts. Acta Pharm Sci 2006;48:5-10.
11. Kumar S, Issarani R, Nagori BP, Ahuja M. Design and evaluation of guar gum based ofloxacin sustained release ocular inserts. Asian J Pharm 2012;6:198-203.
12. Mundada AS, Shrikhande BK. Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert. Curr Eye Res 2008;33:469-75.
13. Jethava JK, Jethava GK. Design, formulation, and evaluation of novel sustain release bioadhesive in-situ gelling ocular inserts of ketorolac tromethamine. Int J Pharma Inves 2014;4:226-32.
14. Shivhare UD, Chavan MA, Bhusari KP, Mathur VB, Kakade VN. Formulation development and evaluation of controlled release ocular insert. Int J Bio-Pharm Res 2012;3:66-74.
15. Tanwar YS, Patel D, Sisodia SS. In vitro and in vivo evaluation of ocular inserts of ofloxacin. DARU 2007;15:139-45.
16. Mohamed AA, Mohamed al-A. Design and evaluation of ciprofloxacin hydrochloride ocular inserts. Int J Pharm Tech Res 2011;3:1750-63.
17. Shanmugam S, Valarmathi S, Satheesh KS. Sterility testing procedure of ophthalmic ocusert acyclovir used for treating herpes simplex virus. Asian J Pharm Clin Res 2017;10:344-6.
18. Kerur S, Dandgi P, Deshpande P. Controlled release polymeric ocular inserts for delivery of acyclovir. Turkish J Pharm Sci 2010;7:75-90.
19. Jayaprakash S, James CC, Maria NS, Saisivam S, Nagarajan M. Design and evaluation of keterolac tromethamine ocuserts. Indian J Pharm Sci 2000;62:334-8.
20. Rao V, Shyale S. Preparation and evaluation of ocular inserts containing norfloxacin. Turkish J Med Sci 2004;34:239-46.
21. Pawar PK, Katara R, Majumdar DK. Design and evaluation of moxifloxacin hydrochloride ocular inserts. Acta Pharma 2012;62:93-104.
22. Nageshwara RG, Ramakrishna A. Formulation design and in vitro evaluation of natamycin ocular insert. Int J Pharm Res Biosci 2014;3:687-95.
23. Jervis LP. A summary of recent advances in ocular inserts and implants. J Bioequi Bioavai 2017;9:320-3.
24. Kumar KPS, Bhowmik D, Harish G, Duraivel S, Kumar BP. Ocular inserts: a novel drug delivery system. Pharma Innov J 2013;1:1-16.
25. Kumar A, Mittal A, Kumar S, Singh A, Gupta A. Effect of gelrite concentration on the release through ocular inserts of ciprofloxacin hydrochloride. J Pharm Res 2009;2:487-90.
26. Pandey P, Panwar AK, Dwivedi P, Jain P, Agarwal A, Jain D. Design and evaluation of ocular inserts for controlled drug delivery of acyclovir. Int J Pharm Bio Arch 2011;2:1106-10.
27. Abraham S, Furtado S, Bharath S, Basavaraj BV, Deveshwaran R, Madhavan V. Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system. Pakistan J Pharm Sci 2009;22:175-9.
28. Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm 2016;109:224-35.
29. Franca JR. Bimatoprost loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro in vivo evaluation. Plos One 2014;9:1-11.
30. Sasaki H. One-side-coated insert as a unique ophthalmic drug delivery system. J Controlled Release 2003;92:241-7.
31. Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. Drug Dev Ind Pharm 2003;29:215-21.
32. Gupta A, Sharma SK, Ahuja M. In vitro and in vivo evaluation of gellan based ocular inserts of phenylephrine. Acta Pharm Sci 2007;49:55-63.
33. Sultana Y, Aquil M, Ali A. Ocular insert for controlled delivery of pefloxacin mesylate: preparation and evaluation. Acta Pharm 2005;55:305-14.
34. Venkateshwar R, Somashekar S. Preparation and evaluation of ocular inserts containing norfloxacin. Tur J Med Sci 2004;34:239-46.
35. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm 2002;28:473-93.
36. Upadhyay N, Patidar A, Agrawal S. Development and evaluation of polymeric sustained release levofloxacin ocuserts. Res J Pharm Bio Chem Sci 2011;2:411â€“21.
37. Mortazavi SA, Jaffariazar Z, Damercheli E. Formulation and in vitro evaluation of ocular ciprofloxacin containing minitablets prepared with different combinations of carbopol 974P and various cellulose derivatives. Iran J Pharm Res 2010;9:107â€“14.